Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
Bristol-Myers Squibb
Yale University
M.D. Anderson Cancer Center
BicycleTx Limited
Nanobiotix
Maastricht University Medical Center
University of Kansas Medical Center
Memgen, Inc.
Incyte Corporation
Bristol-Myers Squibb
Washington University School of Medicine
Exelixis